Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial ...
A new mRNA vaccine developed in Japan has been shown to suppress abnormal blood vessel growth in the retina of mice, offering ...
An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the ...
On 15 September 2025, Regeneron Pharmaceuticals conducted a study is researching an experimental drug called REGN5381 (called ...
An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the ...
News-Medical.Net on MSN
New intramuscular mRNA vaccine offers easier alternative to treat neovascular eye diseases
An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the retina of mouse models.
SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals ...
In a new study, Picture Health's QVT score identified responders and non-responders to immunotherapy and chemoimmunotherapy.
At ASTRO, Artera presented clinical validation data on its prostate cancer test in an Asian population,and showed how the test may complement gene expression-based approaches.
Reston, VA, A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback